Sepranolone for PMDD: Could This New Research Lead to a New Treatment?

Sepranolone is an investigational treatment for premenstrual dysphoric disorder (PMDD) created by Asarina Pharma that aims to reduce the brain’s sensitivity to allopregnanolone, a progesterone-derived neurosteroid.

Early research is promising—particularly for a 10 mg dose—but the main Phase II trial did not meet its prespecified primary symptom endpoint, so it is not yet an established or routinely available PMDD treatment.

Let us break this down!

PMDD is not “just PMS.” It is a serious, cyclical mood disorder that can bring severe irritability, depression, anxiety, mood swings, exhaustion, concentration problems and physical symptoms in the days before a period. Symptoms typically improve shortly after bleeding begins, and diagnosis requires prospective daily symptom tracking across at least two cycles.

Important: If you have thoughts of self-harm, feel unsafe, or fear you may act on suicidal thoughts, seek urgent local emergency or mental-health support now. PMDD deserves prompt, compassionate medical care.

What is sepranolone?

Sepranolone, also called isoallopregnanolone or UC1010, is a synthetic version of a naturally occurring neurosteroid. It is being studied as a treatment that may specifically target the hormone-related brain mechanism thought to drive PMDD symptoms in some people.

Unlike a standard antidepressant, sepranolone is designed around PMDD’s cyclical biology:

• It is a GABA-A receptor-modulating steroid antagonist.

• It is intended to counter the effects of allopregnanolone.

• In the main trial, it was given as a subcutaneous injection every 48 hours during the 14 premenstrual days.

• It is not a supplement, over-the-counter medicine or a treatment to self-source.

Why might allopregnanolone matter in PMDD?

After ovulation, progesterone rises and is converted into allopregnanolone. Allopregnanolone usually has calming effects in the brain through GABA-A receptors; however, researchers hypothesise that some people with PMDD have an atypical or heightened sensitivity to its rise and fall.

This helps explain an important point: PMDD is not necessarily caused by “abnormal hormone levels.” Instead, it may involve a different brain response to normal hormonal changes across the menstrual cycle. The research team led by Professor Torbjörn Bäckström tested whether blocking this neurosteroid-related effect could reduce PMDD symptoms.

How does the proposed mechanism work?

What did the major sepranolone study actually find?

The most important published study was a randomised, double-blind, placebo-controlled Phase II trial published in Psychoneuroendocrinology in 2021. It enrolled 206 people with DSM-5-confirmed PMDD across 12 European centres.

Participants were assigned to placebo, sepranolone 10 mg or sepranolone 16 mg. They received injections every 48 hours during the 14 premenstrual days for three consecutive cycles. Before treatment, the team confirmed PMDD using two cycles of daily ratings on the Daily Record of Severity of Problems (DRSP) e-diary.

What was the primary outcome?

The planned main analysis measured changes in the DRSP’s Sum21 total-symptom score, comparing the average of the five worst premenstrual days in treatment cycles two and three with the diagnostic cycles.

Here is the crucial finding: the prespecified primary analysis did not show a statistically significant difference between sepranolone and placebo, even though all groups—including placebo—showed a substantial improvement.

That means the study cannot be described as a definitive positive trial. A large placebo response and the difficulty of capturing the full PMDD symptom window may have influenced the result.

Did sepranolone improve anything?

Yes, but the findings need careful interpretation. In the prespecified analysis, sepranolone showed a statistically significant benefit for distress compared with placebo, with a p-value of 0.037, while impairment showed a trend favouring the drug.

Researchers then conducted a post-hoc analysis—an analysis decided after seeing the data—focused on nine premenstrual days in the third treatment cycle among people who followed the protocol. In this analysis, the 10 mg dose performed significantly better than placebo for total symptoms, impairment and distress.

Why is the 10 mg finding interesting?

The 10 mg result is notable because it suggests that PMDD treatment may eventually become more precise than simply suppressing ovulation or treating mood symptoms broadly. It also raises the possibility that a treatment could be used only during the symptom-prone part of the cycle.

However, the result came from a post-hoc analysis. In research terms, that means it is hypothesis-generating, not a final answer. A future trial needs to predefine the nine-day window and confirm whether 10 mg reliably outperforms placebo in a larger, diverse group of people with PMDD.

What do professional experts say about sepranolone?

The study authors concluded that sepranolone had an attenuating effect on PMDD symptoms, impairment and distress, “especially” at the 10 mg dose, while also noting that the original primary endpoint was not statistically significant.

A professional clinical review of PMDD management similarly describes the early results as promising but emphasises that a later Phase II extension did not demonstrate superiority over placebo at its primary endpoint; it did, however, find a significant effect on reported distress and a positive post-hoc 10 mg result for the final cycle.

So the balanced professional view is:

• Promising mechanism: It targets a biologically plausible PMDD pathway.

• Potentially useful signal: The 10 mg dose improved outcomes in a secondary, post-hoc analysis.

• Not confirmed enough yet: The primary endpoint was negative.

• More studies are needed: Especially trials designed around the symptom window that best reflects real-world PMDD.

Is sepranolone approved or available for PMDD?

No. Sepranolone remains an investigational treatment and should not be presented as an approved cure or standard prescription option for PMDD. Current PMDD care should be based on established clinical assessment and evidence-based treatments available through a qualified clinician.

If you see social-media posts calling sepranolone “the new PMDD injection” or “a breakthrough cure,” treat those claims cautiously. Research results are not the same as regulatory approval, availability in India, long-term safety evidence or proof that a medicine will work for every person with PMDD.

What treatments can help PMDD now?

PMDD can be treated. A clinician may recommend a combination of symptom tracking, psychological support, medication, hormonal options and lifestyle adjustments based on your symptoms, health history, contraception needs and pregnancy plans.

Common evidence-based care discussions may include:

• SSRIs: Antidepressants can be taken continuously or only in the premenstrual phase; ACOG finds SSRIs highly effective for premenstrual symptoms.

• Combined hormonal contraception: This may be an option for some people, particularly when contraception is also wanted.

• CBT or other psychological therapy: Useful for coping strategies, depressive symptoms, anxiety and the day-to-day impact of PMDD.

• Lifestyle foundations: Regular movement, consistent sleep, reduced caffeine or sugar if these worsen symptoms, and stress support can be helpful alongside—not instead of—clinical care.

• Specialist options: Severe, treatment-resistant PMDD may need gynaecology and mental-health specialist input, including discussion of ovulation suppression.

How can you use cycle tracking to prepare for care?

A detailed record can make a vague monthly pattern visible. For PMDD, track symptoms every day—not only when you feel unwell—and continue for at least two cycles. Official health guidance notes that PMDD diagnosis requires tracking symptoms in relation to the menstrual cycle for a minimum of two months.

What should you track on HealCycle?

Use HealCycle to build a clear, appointment-ready record of:

• Mood changes: sadness, hopelessness, anxiety, irritability, anger and sensitivity to rejection

• Thoughts and cognition: intrusive thoughts, concentration problems, brain fog and feeling overwhelmed

• Physical symptoms: sleep changes, fatigue, breast tenderness, bloating, headaches and food cravings

• Daily functioning: work, study, relationships, caregiving and social withdrawal

• Cycle dates: period start, estimated ovulation and the day symptoms begin and resolve

• Safety concerns: self-harm thoughts, suicidal thoughts or feeling unable to stay safe

A useful appointment statement is: “My symptoms rise after ovulation, peak before my period, improve soon after bleeding begins, and this pattern has occurred across at least two tracked cycles.” This gives your clinician a clearer starting point for distinguishing PMDD from conditions that worsen premenstrually.

What should you ask your doctor about sepranolone research?

Take curiosity about new treatments seriously—but keep the conversation grounded in the evidence. You could ask:

• Do my tracked symptoms meet the pattern expected in PMDD?

• Could another mental-health, thyroid, pain or reproductive condition be worsening before my period?

• Which currently available treatment is most suitable for my symptoms and medical history?

• Would luteal-phase or continuous SSRI treatment be appropriate for me?

• Could contraception or hormone-based treatment help—or worsen—my symptoms?

• Are there legitimate clinical trials or specialist PMDD services I could discuss?

• How should I make a safety plan for severe premenstrual mood symptoms?

What is the bottom line on sepranolone for PMDD?

Sepranolone is one of the more biologically targeted PMDD treatments under study. Its 10 mg dose produced encouraging improvements in a post-hoc analysis, including total symptoms, distress, impairment and the proportion of participants reporting minimal or no symptoms.

But the Phase II trial’s planned primary outcome was not statistically significant versus placebo. Until rigorous confirmatory trials and regulatory review are complete, sepranolone should be viewed as promising research—not a replacement for current PMDD treatment.

Start with the information you can act on today: track daily symptoms, notice your personal timing, and share at least two cycles of HealCycle data with a gynaecologist, psychiatrist or other qualified clinician. Clear tracking can help you move from “I feel terrible every month” to a documented pattern and a treatment plan that takes your experience seriously.

Disclaimer

The information provided in this blog post is for informational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your qualified healthcare provider with any questions you may have regarding a medical condition or before starting any new treatment or making any changes to existing medical care.

References

1. Bäckström T, Ekberg K, Lindén Hirschberg A, et al. A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder. Psychoneuroendocrinology. 2021;133:105426. doi:10.1016/j.psyneuen.2021.105426.

2. Carlini SV, Deligiannidis KM. Management of Premenstrual Dysphoric Disorder: A Scoping Review. Focus (American Psychiatric Publishing). 2024.[pmc.ncbi.nlm.nih]

3. NHS 111 Wales. Premenstrual dysphoric disorder (PMDD). Diagnosis, symptoms and treatment overview.[111.wales.nhs]

4. American College of Obstetricians and Gynecologists. Management of Premenstrual Disorders: ACOG Clinical Practice Guideline. 2023.[semanticscholar]

5. U.S. Food and Drug Administration. Drug Approvals and Databases.[fda]

6. Harvard Health Publishing. Treating Premenstrual Dysphoric Disorder.[health.harvard]